321 related articles for article (PubMed ID: 25116402)
1. Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Schwinger W; Sovinz P; Benesch M; Lackner H; Seidel M; Strenger V; Sperl D; Raicht A; Brunner-Krainz M; Paschke E; Plecko B; Urban C
Pediatr Hematol Oncol; 2014 Nov; 31(8):723-30. PubMed ID: 25116402
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
3. Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
Gonzalez-Vicent M; Perez A; Abad L; Sevilla J; Ramirez M; Diaz MA
J Pediatr Hematol Oncol; 2010 Apr; 32(3):e85-90. PubMed ID: 20216238
[TBL] [Abstract][Full Text] [Related]
4. Haploidentical allogeneic hematopoietic cell transplantation in adults with reduced-intensity conditioning and CD3/CD19 depletion: fast engraftment and low toxicity.
Bethge WA; Haegele M; Faul C; Lang P; Schumm M; Bornhauser M; Handgretinger R; Kanz L
Exp Hematol; 2006 Dec; 34(12):1746-52. PubMed ID: 17157172
[TBL] [Abstract][Full Text] [Related]
5. Transplantation of allogeneic CD34-selected stem cells after fludarabine-based conditioning regimen for children with mucopolysaccharidosis 1H (M. Hurler).
Grigull L; Beilken A; Schrappe M; Das A; Luecke T; Sander A; Stanulla M; Rehe K; Sauer M; Schmid H; Welte K; Lukacs Z; Gal A; Sykora KW
Bone Marrow Transplant; 2005 Feb; 35(3):265-9. PubMed ID: 15580280
[TBL] [Abstract][Full Text] [Related]
6. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
8. Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Cesaro S; Gazzola MV; Marson P; Calore E; Caenazzo L; Destro R; De Silvestro G; Varotto S; Pillon M; Zanesco L; Messina C
Am J Hematol; 2003 Feb; 72(2):143-6. PubMed ID: 12555220
[TBL] [Abstract][Full Text] [Related]
9. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
10. T-cell receptor αβ
Shah RM; Elfeky R; Nademi Z; Qasim W; Amrolia P; Chiesa R; Rao K; Lucchini G; Silva JMF; Worth A; Barge D; Ryan D; Conn J; Cant AJ; Skinner R; Abd Hamid IJ; Flood T; Abinun M; Hambleton S; Gennery AR; Veys P; Slatter M
J Allergy Clin Immunol; 2018 Apr; 141(4):1417-1426.e1. PubMed ID: 28780238
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine.
Ahmed N; Leung KS; Rosenblatt H; Bollard CM; Gottschalk S; Myers GD; Carrum G; Heslop HE; Brenner MK; Krance RA
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1298-304. PubMed ID: 18940685
[TBL] [Abstract][Full Text] [Related]
12. Alternative donor HSCT in refractory acquired aplastic anemia - prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation.
Urban C; Benesch M; Sovinz P; Sipurzynski S; Lackner H; Müller E; Schwinger W
Pediatr Transplant; 2012 Sep; 16(6):577-81. PubMed ID: 22462513
[TBL] [Abstract][Full Text] [Related]
13. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
[TBL] [Abstract][Full Text] [Related]
14. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
[TBL] [Abstract][Full Text] [Related]
15. Substitution of cyclophosphamide and busulfan by fludarabine, treosulfan and melphalan in a preparative regimen for children and adolescents with Shwachman-Diamond syndrome.
Sauer M; Zeidler C; Meissner B; Rehe K; Hanke A; Welte K; Lohse P; Sykora KW
Bone Marrow Transplant; 2007 Feb; 39(3):143-7. PubMed ID: 17211437
[TBL] [Abstract][Full Text] [Related]
16. Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
van Besien K; Devine S; Wickrema A; Jessop E; Amin K; Yassine M; Maynard V; Stock W; Peace D; Ravandi F; Chen YH; Cheung T; Vijayakumar S; Hoffman R; Sosman J
Bone Marrow Transplant; 2003 Jul; 32(1):9-13. PubMed ID: 12815472
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
18. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
19. Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients.
Shukla P; Dvorak CC; Long-Boyle J; Kharbanda S
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781600
[TBL] [Abstract][Full Text] [Related]
20. Treosulfan-Based Conditioning Regimen in Haematopoietic Stem Cell Transplantation with TCRαβ/CD19 Depletion in Nijmegen Breakage Syndrome.
Laberko A; Sultanova E; Gutovskaya E; Radygina S; Deripapa E; Kantulaeva A; Trakhtman P; Brilliantova V; Starichkova J; Shcherbina A; Maschan M; Maschan A; Balashov D
J Clin Immunol; 2020 Aug; 40(6):861-871. PubMed ID: 32602054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
